Category: Fellows Posters
Purpose: In the United States, there are approximately 2,000 snake bites by venomous snakes each year. Anavip® (Crotalidae Immune F(ab’)2 - Equine) was approved in 2018 for the treatment of adult and pediatric patients with North American rattlesnake envenomation. Prior to the approval of Anavip®, the only available rattlesnake antivenom was CroFab® (Crotalidae Polyvalent Immune Fab - Ovine). This retrospective report aims to evaluate the quantity of Anavip® used to treat patients requiring antivenom. The secondary purpose of this report is to compare the health and economic outcomes of patients treated with Anavip® to patients treated with CroFab®.
Seven hospitals within a health system spanning the United States were invited to participate in this retrospective data collection. Hospitals were selected based on CroFab® purchasing history over the past two years. Inclusion criteria are patients treated with Anavip® or CroFab® who are 18 years of age or greater. Hospital pharmacists will collect data on patients retrospectively in accordance with the data collection form and inclusion criteria. Data points include but are not limited to: patient age, patient gender, type of antivenom administered, quantity of antivenom utilized, timing of antivenom administered, type of snake, site of envenomation, anticoagulation laboratory measurements, and wound assessments. Data will be collected and interpreted from various hospitals for an increased sample size. The number of vials of Anavip and the outcomes of patients treated with each antivenom will be reported.